

# Accepted Manuscript



Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study (CIMPACT)

Mark Lebwohl, MD, Andrew Blauvelt, MD, MBA, Carle Paul, MD, PhD, Howard Sofen, MD, Jolanta Węglowska, MD, Vincent Piguet, MD, Daniel Burge, MD, Robert Rolleri, PharmD, Janice Drew, MPH, Luke Peterson, MS, Matthias Augustin, MD

PII: S0190-9622(18)30526-7

DOI: [10.1016/j.jaad.2018.04.013](https://doi.org/10.1016/j.jaad.2018.04.013)

Reference: YMJD 12461

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 6 December 2017

Revised Date: 29 March 2018

Accepted Date: 5 April 2018

Please cite this article as: Lebwohl M, Blauvelt A, Paul C, Sofen H, Węglowska J, Piguet V, Burge D, Rolleri R, Drew J, Peterson L, Augustin M, Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study (CIMPACT), *Journal of the American Academy of Dermatology* (2018), doi: 10.1016/j.jaad.2018.04.013.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: Results Through 48 Weeks of a**  
2 **Phase 3, Multicenter, Randomized, Double-Blinded, Etanercept- and Placebo-Controlled Study**  
3 **(CIMPACT)**

4 Mark Lebwohl, MD,<sup>1</sup> Andrew Blauvelt, MD, MBA,<sup>2</sup> Carle Paul, MD, PhD,<sup>3</sup> Howard Sofen, MD,<sup>4</sup>  
5 Jolanta Węglowska, MD,<sup>5</sup> Vincent Piguët, MD,<sup>6</sup> Daniel Burge, MD,<sup>7</sup> Robert Rolleri, PharmD,<sup>8</sup>  
6 Janice Drew, MPH,<sup>7</sup> Luke Peterson, MS,<sup>8</sup> Matthias Augustin, MD<sup>9</sup>

7 <sup>1</sup>*Icahn School of Medicine at Mount Sinai, New York, NY;* <sup>2</sup>*Oregon Medical Research Center, Portland,*  
8 *Oregon;* <sup>3</sup>*Paul Sabatier University, Toulouse, France;* <sup>4</sup>*David Geffen School of Medicine at UCLA, Los*  
9 *Angeles, CA;* <sup>5</sup>*Niepubliczny Zakład Opieki Zdrowotnej multiMedica, Wrocław, Poland;* <sup>6</sup>*Cardiff*  
10 *University and University Hospital of Wales, Cardiff, UK, University of Toronto and Women's College*  
11 *Hospital, Toronto, Ontario, Canada;* <sup>7</sup>*Dermira, Inc., Menlo Park, CA;* <sup>8</sup>*UCB Pharma, Raleigh, NC;*  
12 <sup>9</sup>*University Medical Center Hamburg-Eppendorf, Hamburg, Germany*

13 **Corresponding Author:**

14 Mark Lebwohl, MD  
15 Icahn School of Medicine at Mount Sinai  
16 New York, NY 10029  
17 Telephone: 212-659-9530  
18 Email: lebwohl@aol.com  
19

20 **Funding Sources:** This study was funded by Dermira, Inc.  
21

22 **IRB Approval Status:** Reviewed and approved by Quorum IRB (file #30064; December 12, 2014).

23 **ClinicalTrials.gov Listing:** NCT02346240

24 **EudraCT Listing:** 2014-003492-36  
25

26 **Conflicts of Interest: ML:** Employee of Mount Sinai, which receives research funds from: AbbVie,  
27 Amgen, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Janssen/Johnson & Johnson, Kadmon,  
28 Medimmune/Astra Zeneca, Novartis, Pfizer, and Vidac. Consultant: Allergan. **AB:** Consulting honoraria,  
29 clinical investigator, and/or speaker's fees: AbbVie, Aclaris, Allergan, Almirall, Amgen, Boehringer  
30 Ingelheim, Celgene, Dermavant, Dermira, Inc., Eli Lilly and Company, Genentech/Roche, GSK, Janssen,  
31 LEO Pharma, Merck Sharp & Dohme, Novartis, Pfizer, Purdue Pharma, Regeneron, Sandoz, Sanofi  
32 Genzyme, Sienna Pharmaceuticals, Sun Pharma, UCB, Valeant, and Vidac. **CP:** Consultant and  
33 investigator: AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly and Company,  
34 Janssen/Johnson & Johnson, LEO Pharma, Novartis, Pierre Fabre, Pfizer, and Sanofi/Regeneron.  
35 **HS:** Consulting honoraria, clinical investigator, and/or speaker's fees: AbbVie, Amgen, Boehringer  
36 Ingelheim, Celgene, Dermira, Inc., Janssen, Eli Lilly, Merck, Novartis, Pfizer, Sun Pharma, UCB, and  
37 Valeant. **JW:** Investigator and/or speaker: Amgen, Celgene, Coherus, Dermira, Inc., Eli Lilly and  
38 Company, Galderma, Janssen, LEO Pharma, Merck, Pfizer, Regeneron, Sandoz, and UCB. **VP:**  
39 Consulting honoraria and/or speaker fees: AbbVie, Almirall, Celgene, Janssen, Novartis, and Pfizer.  
40 Support to VP Department: AbbVie, Almirall, Alliance, Beiersdorf UK Ltd, Biotest, Celgene, Dermal, Eli  
41 Lilly, Galderma, Genus Pharma, GlobeMicro, Janssen-Celag, LaRoche-Posay, L'Oreal, LEO Pharma,  
42 Meda, MSD, Novartis, Pfizer, Sinclair Pharma, Spirit, Stiefel, Samumed, Thornton Ross, TyPham, and

Download English Version:

<https://daneshyari.com/en/article/8714893>

Download Persian Version:

<https://daneshyari.com/article/8714893>

[Daneshyari.com](https://daneshyari.com)